RCT 180 moderate hospitalized COVID-19 patients in Egypt, showing higher ICU admission and longer hospitalization with acetaminophen compared with ibuprofen.
Acetaminophen is also known as paracetamol, Tylenol, Panadol, Calpol, Tempra, Calprofen, Doliprane, Efferalgan, Grippostad C, Dolo, Acamol, Fevadol, Crocin, and Perfalgan.
|
risk of ICU admission, 110.0% higher, RR 2.10, p = 0.047, treatment 21 of 90 (23.3%), control 10 of 90 (11.1%).
|
|
risk of oxygen therapy, 110.0% higher, RR 2.10, p = 0.047, treatment 21 of 90 (23.3%), control 10 of 90 (11.1%).
|
|
hospitalization time, 35.7% higher, relative time 1.36, p = 0.01, treatment 90, control 90.
|
|
risk of no recovery, 33.3% higher, RR 1.33, p = 1.00, treatment 4 of 90 (4.4%), control 3 of 90 (3.3%), day 4, dyspnea.
|
|
risk of no recovery, 75.0% higher, RR 1.75, p = 0.25, treatment 14 of 90 (15.6%), control 8 of 90 (8.9%), day 4, fever.
|
|
risk of no recovery, 92.3% higher, RR 1.92, p = 0.04, treatment 25 of 90 (27.8%), control 13 of 90 (14.4%), day 4, lymphopenia.
|
|
risk of no recovery, 70.0% higher, RR 1.70, p = 0.03, treatment 34 of 90 (37.8%), control 20 of 90 (22.2%), day 4, cough.
|
|
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
|
Sobhy et al., 19 Apr 2023, Double Blind Randomized Controlled Trial, Egypt, peer-reviewed, 6 authors, study period January 2022 - May 2022, this trial compares with another treatment - results may be better when compared to placebo, trial
PACTR202202880140319.
Contact:
dr.amrsobhy2013@gmail.com.
Early Use of Ibuprofen in Moderate Cases of COVID-19 Might be a Promising Agent to Attenuate the Severity of Disease: A Randomized Controlled Trial
Amr Sobhy, Lobna A Saleh, Marwa E L Abdelatty, Marwa E L Abdelatty, Sameh A Refaat, Mohammed Kamal
The Open Anesthesia Journal, doi:10.2174/25896458-v17-e230403-2022-26
Introduction: Critically ill COVID-19 patients undergoing cytokine storm are believed to have a worse prognosis and increased fatality rate. Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAIDs) that might prove beneficial for the early management of COVID-19 due to its immunomodulatory effects. This study aimed to assess the efficacy and safety of the early use of ibuprofen to attenuate the severity of the course of COVID-19 and improve outcomes in patients diagnosed with a moderate case of COVID-19 disease.
Methods: This randomized, double-blinded prospective study was conducted from January, 2022 to May, 2022, which included a total sample size of 180 patients with moderate cases of COVID-19. The number of patients transferred to intensive care was used as a primary outcome with a proposed large effect size (0.8), alfa =0.05, and power=0.80, so 90 cases were included in each group. Secondary outcomes were inflammatory markers: C-Reactive Protein (CRP), serum ferritin, and interleukin-6 (IL-6), duration of hospital stay, and need for ICU admission.
Results: One hundred eighty patients with moderate case of COVID-19 disease were divided in a 1: 1 ratio to receive ibuprofen (IG) or paracetamol (CG). The average age of the included patients was almost 41 years. Statistically significant differences were reported between both groups in terms of improvement in cough symptoms and lymphopenia in IG compared to CG (p= 0.034 and p= 0.044, respectively). Regarding secondary outcomes, statistically, significant differences were reported between the study's groups in terms of the mean number of patients transferred to the ICU in IG compared to the CG (p =0.0.047) and duration of hospitalization (p =0.013), with no significant differences (p > 0.9999) in the occurrence of side effects. Concerning the follow-up of the cytokine storm marker, there was a statistically significant reduction in serum cytokine marker compared to the baseline value (P < 0.05) in the same group. No statistically significant differences were observed when comparing both groups together in terms of serum ferritin level (p =0.570), serum IL-6 level (p =0.580), and CRP level (p =0.401).
Conclusion: It can be concluded that early use of ibuprofen as adjuvant therapy in COVID-19 management is effective and safe to attenuate the severity of diseases and improve outcomes.
STANDARDS OF REPORTING CONSORT guidelines and methodology were followed.
CONFLICT OF INTEREST The authors declare no conflict of interest, financial or otherwise.
SUPPLEMENTARY MATERIALS Supplementary material is available on the Publisher's website.
References
Bhaskar, Sinha, Banach, Mittoo, Weissert et al., None
Fisman, Shapira, Motro, Pines, Tenenbaum et al., None
Hashimoto, Graham, Geraci, Signaling through the [10] prostaglandin I2 receptor IP protects against respiratory syncytial virus-induced illness, J Virol
Kelleni, Early use of non-steroidal anti-inflammatory drugs in
Kelleni, Nitazoxanide/azithromycin combination for
Lu, Zhang, Zhan, Preventing mortality in COVID-19
Mirzaei, Karampoor, Sholeh, Moradi, Ranjbar et al., None
Qin, Zhou, Hu, Dysregulation of immune response in
Thomas, Non-steroidal anti-inflammatory drug use and outcomes of
